Does the presence of NAFLD influence prescribing behaviour in Type 2 diabetes? by Whyte, MB, McGovern, A, Hinton, W, Arrowsmith, B, de Lusignan, S

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD) by Shah, S, Whyte, MB, McGovern, A, Van Vlymen, JN, Hinton, W, Munro, N, de Lusignan, S

Glycaemic trajectories in type 2 diabetes and risk of cardiovascular disease: Exploring the link by Whyte, MB, Joy, M, Hoang, U, Hinton, W, McGovern, A, Munro, N, Mount, JE, Calderara, S, de Lusignan, S

Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism by Hinton, W, Nemeth, B, de Lusignan, S, Field, B, Feher, MD, Munro, N, Roberts, LN, Arya, R, Whyte, MB

Does diabetes increase the risk of venous thromboembolism? by Hinton, W, Nemeth, B, de Lusignan, S, Roberts, L, Arya, R, Field, B, Feher, MD, Munro, N, Whyte, MB

Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): A retrospective cohort study by Woodmansey, C, McGovern, AP, McCullough, KA, Whyte, MB, Munro, NM, Correa, AC, Gatenby, PAC, Jones, SA, De Lusignan, S

Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: a primary care cohort study by Whyte, MB, Joy, M, Hinton, W, McGovern, A, Hoang, U, van Vlymen, J, Ferreira, F, Mount, J, Munro, N, de Lusignan, S

BMI and HbA1c are metabolic markers for pancreatic cancer: matched case-control study using a UK primary care database by Lemanska, A, Price, CA, Jeffreys, N, Byford, R, Dambha-Miller, H, Fan, X, Hinton, W, Otter, S, Rice, R, Stunt, A, Whyte, MB, Faithfull, S, de Lusignan, S